Crash Course Compliance: Preparing for FDA’s “Return to Normalcy”

As companies have adapted their operations to the realities of the COVID-19 pandemic, many have found themselves navigating U.S. drug and device law for the first time.  So far, this process has been significantly simplified by regulatory waivers and emergency use authorizations (EUA), but with the current public health emergency declaration scheduled to expire on October 23, 2020, the time has come for companies to reassess their FDA compliance.  During a webinar briefing, Vorys attorneys Jolie Havens and Mairi Mull discussed where to start and what companies should consider with regard to FDA compliance.

Click here to view the program on-demand.